tradingkey.logo

Trinity Biotech rises after saying it will focus on CGM technology

ReutersMar 13, 2025 1:25 PM

Ireland-based commercial stage biotechnology company Trinity Biotech's TRIB.O shares rise 8.7% to $0.73 premarket

Co says it will strengthen focus on its Continuous Glucose Monitoring (CGM) technology

Says that the successful execution of its comprehensive transformation plan is expected to drive near-term profitability improvements

Co also appoints Barclays as its exclusive financial advisor to support strategic realignment

Up to Wednesday's close, stock had fallen 22.7% so far this year

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI